Julian Upton

Exploring the challenge for pharma in adapting multichannel marketing strategies for the global stage, while trying to refine messages and communicate a brand identity to multiple local audiences.

AstraZeneca’s Habib Bennaceur talks about the key transitions in his career-from local to global-and his current role in positioning AZ’s Farxiga as a drug with the potential to impact the lives of both patients with and without type 2 diabetes.

Philipp Maerz, CEO of Allergopharma talks about how the company has evolved, his recent transition to CEO, and how he plans to expand in the allergy treatment market.

Exploring the advent of data analytics and pharma marketing automation in guiding targeted messaging and brand engagement.

Involving patients more meaningfully in the industry's activities means getting more serious about their emotional wellbeing.

The path for UK life sciences to factor prominently in transition-period maneuvering.

AstraZeneca's Joris Silon outlines the company's efforts in CVRM (Cardiovascular, Renal and Metabolism) and the potential impact on type-2 diabetes and chronic kidney disease of SGLT2 inhibitors such as Forxiga.

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Exploring the roadmap for US-based, R&D-focused biopharma companies seeking to successfully penetrate product markets and reach patients in Europe.

Amy Mahery, last month appointed Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany, discusses her key priorities and how she will draw on her multi-faceted industry experience to approach the challenges ahead.

As the microbiome "moves into the mainstream," Pharm Exec looks at how industry activity in the space is heating up.

Technology grabbing the attention of watchful industry

Amid new findings on today’s C-suite mood and approach to digital transformation, experts-in a panel discussion and wider examinations by Pharm Exec editors-explore the intersection of data and technology and the areas that must evolve to meet the digital health demands of tomorrow.

Corey McCann, president and CEO of Pear Therapeutics, discusses how the prescription digital therapeutics space has evolved in a decade from disruptive concept to an exciting, growing market.

Realizing the full potential of enabling technologies such as AI and machine learning in measuring treatment value and outcomes.

Pharm Exec speaks to Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja about the growing practice of applying AI and machine learning in value-based and outcomes-based contracts.

Rachel Dolhun of The Michael J. Fox Foundation for Parkinson’s Research tells Pharm Exec about how she helps the Foundation to mobilize greater research engagement on both individual and community levels.

William Golden, founder, chairman and CEO of Noveome Biotherapeutics, talks about the potential of the company's lead product, ST266.

Pharm Exec speaks with Geoff MacKay, co-founder and CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies, his career building businesses and innovation in regenerative medicine, and his most important quest to date-moving gene therapy into the mainstream.

Matthias Wernicke, General Manager of Merck KGaA’s Biopharma business in Russia, talks about how the country is transitioning from an emerging to a mature pharmaceutical market.

A look at some of the key pharma compliance challenges prevalent in the Asia-Pacific region.

Cell One Partners' George Goldberger discusses the issues that new and emerging cell and gene therapy companies face on the road to commercialisation.

See Li Lynn, LEO Pharma’s HR Manager, South Asia, talks about how LEO is managing the compliance challenges in Asia.

Bruno Wohlschlegel, European head of Merck KGaA, Darmstadt, Germany's Healthcare business, outlines the highlights of his career and talks about how his vision for Europe draws strength from the region’s diversity to advance collaboration and progress.

Chris Round, Head of International Operations & Global Core Franchises at Merck KGaA, Darmstadt, Germany talks to Pharm Exec about how the company's new treatments are positioned to advance the company’s “double mission."

Pharm Exec's European Editor, Julian Upton, speaks with Johnson & Johnson's Jennifer Turgiss, VP Behavior Science & Advanced Analytics group. In their interview, Turgiss discusses behavioral strategies to the health and wellness solutions being developed at J&J.

Pair of interviews spotlight the changing dynamics for C-suite business managers in two contrasting life sciences settings-big, established pharma and small, aggressive biotech.

Mundipharma CFO Arnaud Breakout talks about how he has seen the CFO role evolve over his 20-plus years in the life sciences industry.

Esperion CFO Rick Bartram highlights his involvement in the young organization's success over the last six years and discusses the company mission means to him.

Pharm Exec's European Editor, Julian Upton, caught up with Ben Wiegand, head of J&J's World Without Disease Accelerator unit, at eyeforpharma Barcelona. They talk about Wiegand's panel "Uniting Patients, Providers, and Payers to Bring Preventative Care to Life," and J&J's disease prevention and interception activities.